Ambroxol influences voriconazole resistance of Candida parapsilosis biofilm.
The ability to form biofilm on different surfaces is typical of most Candida species. Microscopic structure and genetic aspects of fungal biofilms have been the object of many studies because of very high resistance to antimycotic agents because of the scarce permeability of the external matrix and to the alterations in cell metabolism. In our study, 31 isolates of Candida parapsilosis, isolated from bloodstream infections, were tested for their ability to produce biofilm and were found to be good producers. The susceptibility to voriconazole, assayed by colorimetrical XTT assay, revealed a very elevated minimum inhibitory concentrations for sessile cells in comparison with planktonic ones. The addition of ambroxol, a mucolytic agent, increased the susceptibility of biofilm forming cells to voriconazole. Expression of the efflux pump genes CDR and MDR was analyzed in biofilms alone or treated with ambroxol, evidencing a role of ambroxol in the expression of genes involved in azole resistance mechanisms of C. parapsilosis biofilms. In conclusion, our data seem to encourage the use of different substances in combination with classical antimycotics, with the aim of finding a solution to the increasing problem of the resistance of biofilms formed on medical devices by nonalbicans Candida species.
Department of Cellular and Molecular Biology and Pathology "Luigi Califano", Medicine School, University of Naples "Federico II", Naples, Italy. giovannapulcrano@libero.it
Giovanna
G
Pulcrano
Dimitrios
D
Panellis
Giovanni
G
De Domenico
Fabio
F
Rossano
Maria Rosaria
MR
Catania
D000551:Ambroxol / Q000494:pharmacology*; D000935:Antifungal Agents / Q000494:pharmacology*; D018441:Biofilms / Q000187:drug effects*; D002175:Candida / Q000187:drug effects* / Q000302:isolation & purification / Q000502:physiology*; D003124:Colorimetry; D004357:Drug Synergism; D016469:Fungemia / Q000382:microbiology; D006801:Humans; D008826:Microbial Sensitivity Tests; D050296:Microbial Viability / Q000187:drug effects; D011743:Pyrimidines / Q000494:pharmacology*; D013778:Tetrazolium Salts / Q000378:metabolism; D014230:Triazoles / Q000494:pharmacology*; D065819:Voriconazole
D000935:Antifungal Agents; D011743:Pyrimidines; D013778:Tetrazolium Salts; D014230:Triazoles; C059087:2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-((phenylamino)carbonyl)-2H-tetrazolium hydroxide; D000551:Ambroxol; D065819:Voriconazole